- Home
- SPXX vs ESPR Comparison
SPXX vs ESPR Comparison
Compare SPXX & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPXX
- ESPR
- Stock Information
- Founded
- SPXX 2004
- ESPR 2008
- Country
- SPXX United States
- ESPR United States
- Employees
- SPXX N/A
- ESPR N/A
- Industry
- SPXX Trusts Except Educational Religious and Charitable
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- SPXX Finance
- ESPR Health Care
- Exchange
- SPXX Nasdaq
- ESPR Nasdaq
- Market Cap
- SPXX 329.9M
- ESPR 305.0M
- IPO Year
- SPXX N/A
- ESPR 2013
- Fundamental
- Price
- SPXX $16.95
- ESPR $1.69
- Analyst Decision
- SPXX
- ESPR Buy
- Analyst Count
- SPXX 0
- ESPR 7
- Target Price
- SPXX N/A
- ESPR $6.36
- AVG Volume (30 Days)
- SPXX 51.3K
- ESPR 4.2M
- Earning Date
- SPXX 01-01-0001
- ESPR 03-04-2025
- Dividend Yield
- SPXX 7.55%
- ESPR N/A
- EPS Growth
- SPXX N/A
- ESPR N/A
- EPS
- SPXX N/A
- ESPR N/A
- Revenue
- SPXX N/A
- ESPR $332,314,000.00
- Revenue This Year
- SPXX N/A
- ESPR $5.51
- Revenue Next Year
- SPXX N/A
- ESPR $1.42
- P/E Ratio
- SPXX N/A
- ESPR N/A
- Revenue Growth
- SPXX N/A
- ESPR 185.66
- 52 Week Low
- SPXX $13.57
- ESPR $1.47
- 52 Week High
- SPXX $16.05
- ESPR $3.94
- Technical
- Relative Strength Index (RSI)
- SPXX 32.30
- ESPR 49.78
- Support Level
- SPXX $16.78
- ESPR $1.47
- Resistance Level
- SPXX $17.09
- ESPR $1.61
- Average True Range (ATR)
- SPXX 0.28
- ESPR 0.12
- MACD
- SPXX -0.07
- ESPR 0.02
- Stochastic Oscillator
- SPXX 20.63
- ESPR 56.41
About SPXX Nuveen S&P 500 Dynamic Overwrite Fund
Nuveen S&P 500 Dynamic Overwrite Fund is a diversified closed-end management investment company. Its investment objective is to seek attractive total returns with less volatility than the S&P 500 Index by investing in a U.S. equity portfolio that seeks to substantially replicate the price movements of the S&P 500 Index, as well as selling call options on 35%-75% of the notional value of the Fund's equity portfolio (with a 55% long-term target) in an effort to enhance the Fund's risk-adjusted returns.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.